Gregory J. Duman
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jonathon Skeels | M | 42 | 6 years | |
| Martin Massengale | M | 90 |
University of Nebraska
| 48 years |
| Richard Chernicoff | M | 59 | 6 years | |
| Conner Mowles | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hussein A. Enan | M | 79 | 23 years | |
| Craig J. Tuttle | M | 71 |
Transgenomic, Inc.
 Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 7 years |
| Gregory T. Sloma | M | 71 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE.
University of Nebraska
| 10 years |
| David C. Russell | M | - | 12 years | |
| Debra Ann Schneider | F | 65 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | - |
| Richard A. Natsch | M | 51 | 1 years | |
| William E. Fisher | M | 77 | 8 years | |
| Steven J. Yasuda | M | 57 | 19 years | |
| Jerri Ann Thompson | F | - |
University of Nebraska
| 7 years |
| Chad M. Richards | M | 54 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 6 years |
| Eugenia Marie Simpson | F | - |
University of Nebraska
| 6 years |
| Elisabeth DeMarse | F | 69 | 1 years | |
| Thomas W. Orr | M | 90 | 13 years | |
| Gregory Wells | M | 67 |
University of Nebraska
| 5 years |
| Jeremy Wilmot | M | - | 23 years | |
| Larry G. Fendley | M | - | 7 years | |
| Mitchell L. Murphy | M | - |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | - |
| Rodney Markin | M | 67 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 7 years |
| Robert A. Puccinelli | M | 87 | 14 years | |
| L. James Pickles | M | 60 | 9 years | |
| Dennis Chookaszian | M | 80 | 14 years | |
| Cynthia Susan Hahn | F | - |
University of Nebraska
| 7 years |
| John Leonard | M | - |
University of Nebraska
| 10 years |
| Michael Summers | M | - |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | - |
| Michael Draper | M | 58 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 4 years |
| James M. Corroon | M | 85 | 21 years | |
| Bill Shreve | M | - |
University of Nebraska
| 4 years |
| Richard M. Poppe | M | - |
University of Nebraska
| 4 years |
| James W. Barton | M | - |
University of Nebraska
| 4 years |
| Andrew R. Berger | M | - |
University of Nebraska
| 4 years |
| Bob Maher | M | - |
University of Nebraska
| 4 years |
| Petter M. Etholm | M | - |
Thomas Equipment, Inc.
| 1 years |
| Luigi Lo Basso | M | - |
Thomas Equipment, Inc.
| - |
| Mike Wofford | M | - | 13 years | |
| Caroline J. Miller | F | - |
University of Nebraska
| 4 years |
| Michael Murman | M | - |
University of Nebraska
| 4 years |
| Rick Villars | M | - |
University of Nebraska
| 6 years |
| Patrick L. Pope | M | - |
University of Nebraska
| 4 years |
| Jeffrey J. Prosser | M | - |
University of Nebraska
| 4 years |
| Thomas M. Galvin | M | - |
University of Nebraska
| 4 years |
| Judith Scarpello | F | 63 |
University of Nebraska
| 4 years |
| Doug Weedin | M | - |
University of Nebraska
| 4 years |
| William Alan Oldfather | M | - |
University of Nebraska
| 4 years |
| Mazen Alnaimi | M | - |
University of Nebraska
| 4 years |
| Bob Michaud | M | - |
University of Nebraska
| 4 years |
| John Dinovo | M | - |
University of Nebraska
| 4 years |
| Stephen V. Glenn | M | - |
University of Nebraska
| 4 years |
| Dick Poppe | M | - |
University of Nebraska
| 4 years |
| Edward Conrath | M | - |
University of Nebraska
| 4 years |
| Jeff Finn | M | - |
University of Nebraska
| 4 years |
| Michael B. Spiegel | M | - |
University of Nebraska
| 4 years |
| Barry Ballou | M | - |
University of Nebraska
| 1 years |
| James F. Burke | M | - |
University of Nebraska
| 3 years |
| James W. Allen | M | - |
University of Nebraska
| 4 years |
| Myles James Watts | M | 73 |
University of Nebraska
| 3 years |
| Kerry McGrath | M | - |
University of Nebraska
| 4 years |
| Darren Hellbusch | M | - |
University of Nebraska
| 4 years |
| Chun Ki Ho | M | 67 |
University of Nebraska
| 4 years |
| Mark L. Johnson | M | - |
University of Nebraska
| 4 years |
| Joseph L. Jackson | M | 63 |
University of Nebraska
| 4 years |
| David A. Roehr | M | 66 |
University of Nebraska
| 4 years |
| Jerry E. Beyke | M | - |
University of Nebraska
| 4 years |
| Marcia Ann Koory | F | - |
University of Nebraska
| 4 years |
| Stephen R. Frantz | M | - |
University of Nebraska
| 4 years |
| Kenneth L. Shirley | M | - |
Thomas Equipment, Inc.
| - |
| Mark Borer | M | 70 |
University of Nebraska
| 4 years |
| William Lester | M | - |
University of Nebraska
| 4 years |
| Roland J. Santoni | M | - |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | - |
| Michael P. Crosson | M | - | - | |
| Kurt D. Halvorson | M | 61 |
University of Nebraska
| 4 years |
| Douglas D. Goodyear | M | - |
University of Nebraska
| 3 years |
| Michael W. Woods | M | - |
Thomas Equipment, Inc.
| - |
| James A. Barnes | M | 69 |
University of Nebraska
| 4 years |
| John Wilson | M | 68 |
University of Nebraska
| 4 years |
| David M. Marks | M | 56 |
Thomas Equipment, Inc.
| 4 years |
| Mark McManigal | M | 64 |
University of Nebraska
| 4 years |
| Radha Lai | F | - |
University of Nebraska
| 4 years |
| Judith Hand | F | 62 |
University of Nebraska
| 5 years |
| Bruce McClatchey | M | - |
University of Nebraska
| 4 years |
| Michael Prosser | M | - |
University of Nebraska
| 4 years |
| Julie L. Stafford | F | - |
University of Nebraska
| 4 years |
| Steve Lococo | M | 67 |
University of Nebraska
| 4 years |
| Marvin P. Ehly | M | 70 |
University of Nebraska
| 4 years |
| Kevin Wayne Hammond | M | 64 |
University of Nebraska
| 4 years |
| Richard B. Williams | M | - |
University of Nebraska
| 4 years |
| Leslie Roe Andersen | F | - |
University of Nebraska
| 4 years |
| Steven L. Polacek | M | 64 |
University of Nebraska
| 4 years |
| Ronald Greeno | M | - |
University of Nebraska
| 3 years |
| David R. Andersen | M | - |
University of Nebraska
| 4 years |
| James H. Strong | M | - |
University of Nebraska
| 2 years |
| Stephen Kerns | M | - |
University of Nebraska
| 4 years |
| Paul King | M | - |
University of Nebraska
| 4 years |
| Sally Else | F | - |
University of Nebraska
| 4 years |
| Julie Keegan | F | - |
University of Nebraska
| 4 years |
| Randy K. Rouse | M | - |
University of Nebraska
| 4 years |
| Linda Laskowski | F | - |
University of Nebraska
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gregory J. Duman
- Personal Network
